CI is expected to report earnings to rise+6.45% to $5.28 per share on May 05
CI (Cigna Corporation) is set to report its earnings on May 05, and the financial world is anticipating a 6.45% increase in earnings to $5.28 per share. This news has generated a lot of buzz among investors and analysts, who are closely monitoring the company's financial performance.
Cigna is a major player in the healthcare industry, providing a range of health insurance and related services to customers across the United States. The company's earnings report is a crucial indicator of its financial health and provides valuable insights into its growth prospects.
The expected 6.45% increase in earnings per share is a positive sign for Cigna and its investors, suggesting that the company's business is performing well and is on track for continued growth. However, it is important to note that earnings forecasts are just that - forecasts - and there is always some degree of uncertainty surrounding such predictions.
Investors and analysts will be closely scrutinizing Cigna's earnings report for any signs of weakness or areas of concern. They will be looking at factors such as revenue growth, profit margins, and cash flow to assess the company's financial health and growth potential.
In addition to its financial performance, Cigna is also facing a rapidly changing healthcare landscape, with new regulations, technological advancements, and shifting consumer preferences all impacting the industry. The company's ability to adapt and innovate in response to these challenges will be a key factor in its long-term success.
Overall, the anticipated increase in earnings per share is a positive development for Cigna and its investors, but it is important to approach such forecasts with a degree of caution and to closely monitor the company's performance and broader industry trends in the coming months and years.
CI in upward trend: price rose above 50-day moving average on November 26, 2024
CI moved above its 50-day moving average on November 26, 2024 date and that indicates a change from a downward trend to an upward trend. In of 41 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CI's RSI Oscillator exited the oversold zone, of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on November 27, 2024. You may want to consider a long position or call options on CI as a result. In of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CI just turned positive on November 07, 2024. Looking at past instances where CI's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CI advanced for three days, in of 343 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for CI moved below the 200-day moving average on November 14, 2024. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CI broke above its upper Bollinger Band on November 11, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.234) is normal, around the industry mean (3.063). P/E Ratio (20.936) is within average values for comparable stocks, (17.509). Projected Growth (PEG Ratio) (0.928) is also within normal values, averaging (1.089). Dividend Yield (0.014) settles around the average of (0.020) among similar stocks. P/S Ratio (0.554) is also within normal values, averaging (0.684).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a provider of health insurance services
Industry ManagedHealthCare